Arnab Chakrabarty

Affiliations: 
Cortical Column in silico unknown, Charlotte, NC, United States 
Area:
Network Oscillations, Calcium Imaging, Synaptic Plasticity in the Hippocampus, FRET imaging, Barrel Cortex, Visual Cortex.
Website:
http://www.neuro.mpg.de
Google:
"Arnab Chakrabarty"
Mean distance: 12.51 (cluster 6)
 
SNBCP
BETA: Related publications

Publications

You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect.

Khan A, Manna K, Das DK, et al. (2015) Gossypetin ameliorates ionising radiation induced oxidative stress in mice liver-a molecular approach. Free Radical Research. 1-42
Rexer BN, Ghosh R, Narasanna A, et al. (2013) Human breast cancer cells harboring a gatekeeper T798M mutation in HER2 overexpress EGFR ligands and are sensitive to dual inhibition of EGFR and HER2. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 19: 5390-401
Khan A, Manna K, Bose C, et al. (2013) Gossypetin, a naturally occurring hexahydroxy flavone, ameliorates gamma radiation-mediated DNA damage. International Journal of Radiation Biology. 89: 965-75
Chakrabarty A, Bhola NE, Sutton C, et al. (2013) Trastuzumab-resistant cells rely on a HER2-PI3K-FoxO-survivin axis and are sensitive to PI3K inhibitors. Cancer Research. 73: 1190-200
Chakrabarty A, Sánchez V, Kuba MG, et al. (2012) Feedback upregulation of HER3 (ErbB3) expression and activity attenuates antitumor effect of PI3K inhibitors Proceedings of the National Academy of Sciences of the United States of America. 109: 2718-2723
Garrett JT, Chakrabarty A, Arteaga CL. (2011) Will PI3K pathway inhibitors be effective as single agents in patients with cancer? Oncotarget. 2: 1314-1319
Cook RS, Garrett JT, Sánchez V, et al. (2011) ErbB3 ablation impairs PI3K/Akt-dependent mammary tumorigenesis Cancer Research. 71: 3941-3951
Garrett JT, Olivares MG, Rinehart C, et al. (2011) Transcriptional and posttranslational up-regulation of HER3 (ErbB3) compensates for inhibition of the HER2 tyrosine kinase. Proceedings of the National Academy of Sciences of the United States of America. 108: 5021-6
Ghosh R, Narasanna A, Wang SE, et al. (2011) Trastuzumab has preferential activity against breast cancers driven by HER2 homodimers. Cancer Research. 71: 1871-82
Dave B, Migliaccio I, Gutierrez MC, et al. (2011) Loss of phosphatase and tensin homolog or phosphoinositol-3 kinase activation and response to trastuzumab or lapatinib in human epidermal growth factor receptor 2-overexpressing locally advanced breast cancers. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 166-73
See more...